Literature DB >> 19826812

Type I interferons inhibit the generation of tumor-associated macrophages.

Lance U'Ren1, Amanda Guth, Debra Kamstock, Steven Dow.   

Abstract

Tumor-associated macrophages (TAM) are very abundant in tumors and are thought to play a major role in promoting tumor growth. The generation of TAM is positively regulated by several cytokines, including colony stimulating factor-1 (CSF-1) and monocyte chemoattractant protein-1 (CCL2). However, endogenous factors that suppress the generation of TAM within tumors have not been previously identified. An earlier study showed that endogenously produced type I interferons (IFN) suppressed tumor growth via their effects on hematopoietic cells rather than through direct effects on tumor cells. Therefore, we used mouse tumor models to investigate the effects of endogenously produced type I IFNs on the generation of TAM. We found using immunohistochemistry and flow cytometry that TAM density was significantly increased in tumors of mice lacking the type I IFN receptor (IFN-alpha/betaR(-/-) mice) compared to wild type mice. Moreover, the increase in TAM density was associated with a significant increase in tumor growth rate and angiogenesis. The phenotype of TAM was similar in IFN-alpha/betaR(-/-) mice and wild type mice and tumors in both mice produced similar amounts of CSF-1 and CCL2. However, in vitro assays indicated that low concentrations of type I IFNs significantly inhibited the generation of bone marrow macrophages in response to CSF-1. These findings indicate that endogenously produced type I IFNs suppress the generation of TAM, which may in turn account for inhibition of tumor growth and angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19826812      PMCID: PMC2892738          DOI: 10.1007/s00262-009-0776-6

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  55 in total

1.  Loss of phospholipid asymmetry and surface exposure of phosphatidylserine is required for phagocytosis of apoptotic cells by macrophages and fibroblasts.

Authors:  V A Fadok; D L Daleke; P M Henson; D L Bratton
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival.

Authors:  I F Lissbrant; P Stattin; P Wikstrom; J E Damber; L Egevad; A Bergh
Journal:  Int J Oncol       Date:  2000-09       Impact factor: 5.650

Review 3.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

4.  Chemotactic migration of mesencephalic neural crest cells in the mouse.

Authors:  Y Kubota; K Ito
Journal:  Dev Dyn       Date:  2000-02       Impact factor: 3.780

5.  Expression of HIF-1alpha by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy.

Authors:  Bernard Burke; Ngai Tang; Kevin P Corke; Dean Tazzyman; Kurosh Ameri; Michael Wells; Claire E Lewis
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

Review 6.  Interferon in the management of neuroendocrine GEP-tumors: a review.

Authors:  K Oberg
Journal:  Digestion       Date:  2000       Impact factor: 3.216

Review 7.  Chemokines in the recruitment and shaping of the leukocyte infiltrate of tumors.

Authors:  Alberto Mantovani; Paola Allavena; Silvano Sozzani; Annunciata Vecchi; Massimo Locati; Antonio Sica
Journal:  Semin Cancer Biol       Date:  2004-06       Impact factor: 15.707

8.  A role for IFN-alpha beta in virus infection-induced sensitization to endotoxin.

Authors:  L Doughty; K Nguyen; J Durbin; C Biron
Journal:  J Immunol       Date:  2001-02-15       Impact factor: 5.422

9.  Evidence for the causal role of endogenous interferon-alpha/beta in the regulation of angiogenesis, tumorigenicity, and metastasis of cutaneous neoplasms.

Authors:  Marya F McCarty; Diane Bielenberg; Cherrie Donawho; Corazon D Bucana; Isaiah J Fidler
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy.

Authors:  E Y Lin; A V Nguyen; R G Russell; J W Pollard
Journal:  J Exp Med       Date:  2001-03-19       Impact factor: 14.307

View more
  6 in total

1.  HLA class II expression on tumor cells and low numbers of tumor-associated macrophages predict clinical outcome in oropharyngeal cancer.

Authors:  Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer
Journal:  Head Neck       Date:  2018-12-14       Impact factor: 3.147

Review 2.  Opposing Roles of Type I Interferons in Cancer Immunity.

Authors:  Giselle M Boukhaled; Shane Harding; David G Brooks
Journal:  Annu Rev Pathol       Date:  2020-12-02       Impact factor: 23.472

Review 3.  Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.

Authors:  Gabor J Szebeni; Csaba Vizler; Lajos I Nagy; Klara Kitajka; Laszlo G Puskas
Journal:  Int J Mol Sci       Date:  2016-11-23       Impact factor: 5.923

4.  Concomitant type I IFN and M-CSF signaling reprograms monocyte differentiation and drives pro-tumoral arginase production.

Authors:  Yuanyuan Tong; Luyang Zhou; Limin Yang; Panpan Guo; Yanlan Cao; F Xiao-Feng Qin; Jianghuai Liu
Journal:  EBioMedicine       Date:  2018-12-07       Impact factor: 8.143

Review 5.  The Function of cGAS-STING Pathway in Treatment of Pancreatic Cancer.

Authors:  Ghazal Mohseni; Juan Li; Abakundana Nsenga Ariston Gabriel; Lutao Du; Yun-Shan Wang; Chuanxin Wang
Journal:  Front Immunol       Date:  2021-11-09       Impact factor: 7.561

Review 6.  Modulation of Type I Interferon Responses to Influence Tumor-Immune Cross Talk in PDAC.

Authors:  Carlotta Cattolico; Peter Bailey; Simon T Barry
Journal:  Front Cell Dev Biol       Date:  2022-02-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.